Landscapes / Companies
Suzhou Zelgen Biopharmaceuticals Co.,Ltd not checked
FollowEvery new trial, moved date and filing, and a Monday email
Furthest along
2 in Phase 3
2 in Phase 2
Drugs
4
in active trials · 17 in all
Trials
21 active
78 since 2021
Drugs4
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
— |
Phase 3 | Apr 2027Phase 1/2 trial completes | |||
| Next date | Apr 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Advanced Solid Tumor, Lymphoma and 7 more | ||||
| Open drug page | |||||
— |
Phase 3 | Apr 2027Phase 1/2 trial completes | |||
| Next date | Apr 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Small Cell Lung Cancer, Neuroendocrine Carcinoma and 5 more | ||||
| Open drug page | |||||
Janus kinase inhibitor |
Phase 1/2 | Apr 2027Phase 1/2 trial completes | |||
| How it works | Blocks JAK enzymes that pass on immune signals | ||||
| Next date | Apr 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Lymphoma, Non-small Cell Lung Cancer and 2 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | May 2027Phase 1/2 trial completes | |||
| Next date | May 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Advanced Solid Tumor | ||||
| Open drug page | |||||
About
- No active trial
- 13 other drugs
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 Industry-sponsored drug trials since 2021